Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Ono’s Deciphera drops early-stage solid tumor drug for strategic reasons

Ono’s Deciphera drops early-stage solid tumor drug for strategic reasons

  • March 3, 2026

Ono Pharmaceutical subsidiary Deciphera Pharmaceuticals has dropped an early-stage candidate for advanced cancers from its pipeline, citing strategic reasons unrelated to the asset’s safety or efficacy.

Leave A Comment

Fields (*) Mark are Required